<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03959345</url>
  </required_header>
  <id_info>
    <org_study_id>2018-001207-37</org_study_id>
    <nct_id>NCT03959345</nct_id>
  </id_info>
  <brief_title>Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Adult Patients With Methicillin-susceptible Staphylococcus Aureus Bacteraemia: the SAFO Trial.</brief_title>
  <acronym>SAFO</acronym>
  <official_title>Multicenter, Randomised, Open-label Phase III-IV Study to Evaluate the Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Adult Patients With Methicillin-susceptible Staphylococcus Aureus Bacteraemia: the SAFO Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Miquel Pujol</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut d'Investigació Biomèdica de Bellvitge</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut d'Investigació Biomèdica de Bellvitge</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Despite management improvement in lasts years, Staphylococcus aureus bacteraemia
      leads to high morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus
      (MSSA) bacteraemia standard treatment was cloxacillin. Previous studies using different
      therapies and combination treatment fall to improve survival in these patients.

      Investigator's study aims to demonstrate the efficacy of the cloxacillin and fosfomycin
      combination administered during the first week of treatment, compared with cloxacillin
      monotherapy in patients with MSSA bacteraemia in treatment success. Methods: A multicentre,
      superiority, open-label, randomized, phase IV-III, two-armed parallel (1:1) groups clinical
      trial. Adult patients with MSSA bacteraemia will be randomized to Combination therapy group:
      patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of
      7 days treatment, or Standard therapy group: patients will receive intravenous cloxacillin
      2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and
      duration will be decided by responsible clinician following clinical practice.

      The primary endpoint is the treatment success measured at day 7 of treatment; a composite
      endpoint defined by all of the following criteria met after randomization: patient alive at
      day 7 AND stable or improved quick SOFA score (compared with baseline) at day 7 AND fever
      resolved at day 7 AND blood cultures negative for S. aureus starting at day 7 until Test of
      Cure visit (TOC, 12 weeks after randomization) and no isolation of S. aureus in another
      sterile site from day 8 until TOC. In case of achieving statistical differences in the
      primary endpoint, investigators will perform a hierarchical analysis of the treatment success
      at TOC, defined by presence of all of the following: patient alive AND no evidence of
      microbiological treatment failure defined as persistence of S. aureus bloodstream infection &gt;
      7 days and no isolation of S. aureus from sterile site &gt; 14 days from randomization until
      TOC. Investigators have assumed a 74% of treatment success in monotherapy group. Accepting an
      alpha risk of 0.05 and a beta risk of 0.2 in a two-sided test, 183 subjects are necessary in
      first group and 183 in the second to find a statistically significant difference of 12%. It
      has been anticipated a drop-out rate of 5%.

      Treatment failure is defined by the presence of one of the following condition: all cause
      mortality at 7 days, withdraw of the study because of adverse events, requirement of an
      additional MSSA-active antibiotic until day 7, lacking of clinical improvement.

      Discussion: Randomized studies assessing efficacy of different treatment in MSSA bacteraemia
      are lacking. This study could help to improve knowledge about MSSA bacteraemia and whether
      combined treatment with cloxacillin and fosfomycin could improve outcomes compared with
      standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      SAFO trial is a multicentre, superiority, open-label, randomized, phase IV-III, two-armed
      parallel (1:1) groups clinical trial comparing combination treatment with fosfomycin and
      cloxacillin with standard therapy with cloxacillin in adult patients with MSSA bacteraemia.

      Patients will be randomized to:

        -  Standard treatment group: patients will receive intravenous cloxacillin 2g/4h for the
           duration of 7 days IV treatment. If creatinine clearance is &lt;30 mL/min cloxacillin will
           be administrated at dose of 2g every 6 hours.

        -  Combination therapy group: patients will receive intravenous cloxacillin as explained
           above and fosfomycin 3 g/6h for the duration of 7 days treatment. In case of renal
           failure, fosfomycin will be administrated as follow:

      Creatinine clearance (mL/min) Fosfomycin dosage &gt;40 3 g every 6 hours 20-40 3 g every 12
      hours 10-20 3g every 24 hours &lt;10 3 g every 48 hours Haemodialysis 3 g after haemodialysis
      Continuous renal replacement therapy 3 g every 24h hours

      . This part of treatment will be called &quot;study treatment cycle&quot;. The individual duration of
      overall antibiotic treatment and the duration of intravenous treatment will be determined
      according to clinical criteria depending on status (complicated or uncomplicated bacteraemia,
      source of infection…) by responsible clinician according with current guidelines. Patient
      with complicated bacteraemia will receive at least 4-6 week of antibiotic treatment.
      &quot;Completed treatment cycle&quot; includes the &quot;study treatment cycle&quot; and the posterior antibiotic
      treatment.

      Primary endpoint

      Treatment success at day 7 is a composite outcome defined by all of the following criteria
      met after randomization:

        -  Patient alive at day 7 AND

        -  Clinical improvement measured by stable or improved quick SOFA score (compared with
           baseline) at day 7 AND

        -  Fever resolved at day 7 AND

        -  Blood cultures negative for S. aureus starting at day 7 until TOC visit (12 weeks after
           randomization) and no isolation of S. aureus in another sterile site from day 8 until
           TOC visit.

      In case of statistical differences observed between groups in the primary endpoint,
      investigators will perform a hierarchical testing analyzing the treatment success at TOC
      visit, defined by presence of all of the following patient alive AND no evidence of
      microbiologically confirmed treatment failure defined as persistence of S. aureus blood
      stream infection &gt; 7 days and no isolation of S. aureus from sterile site (e.g. blood, joint
      fluid, tissues) &gt; 14 days from randomization until TOC visit.

      Treatment failure is defined by the presence of one of the following condition: all cause
      mortality, withdraw of the study because of adverse events, requirement of an additional
      MSSA-active antibiotic until day 7, lacking of clinical improvement.

      Secondary endpoint

      Clinical secondary endpoints:

        -  To compare all-cause mortality at days 7, 14, EOT and 90 after randomization in
           cloxacillin treatment group versus cloxacillin and fosfomycin treatment group.

        -  To evaluate persistent bacteraemia (at least one positive blood culture) at day 3 and
           persistent bacteraemia at day 7 after randomization in the two arms of treatment.

        -  To determine the microbiological relapse as defined by at least one positive blood
           culture for MSSA at least 72 hours after a preceding negative culture in the two arms of
           treatment.

        -  To evaluate microbiological treatment failure as defined by positive sterile site
           culture for MSSA at least 14 days after randomisation in the two arms.

        -  To determine the number of patients with persistent and relapsing bacteraemia in the two
           arms of treatment.

        -  To evaluate the number of patients with complicated bacteraemia, defined by persistent
           bacteraemia, endocarditis or metastatic emboli, prosthetic devices) in the two arms of
           treatment.

        -  To determine the length of stay in intensive care unit and in hospital in both arms of
           treatment.

        -  Duration of intravenous antibiotic treatment. Sub group analysis for patients at high
           risk (persistent bacteraemia, metastatic infection, unknown focus of bacteraemia,
           endocarditis, pneumonia).

      Microbiological secondary endpoints:

        -  To determine emergency of fosfomycin-resistant strains during therapy in the arm of
           combination treatment.

        -  To evaluate operon agr functionality and its relationship with Minimum Inhibitory
           Concentration (MIC) changes to vancomycin (VAN) and daptomycin (DAP) and with biofilm
           production.

        -  To analyze VAN and DAP MIC as markers of complications during bacteraemia.

        -  To determine the &quot;in vitro&quot; cloxacillin plus fosfomycin combination synergy.

        -  To realize whole genome sequencing and its changes in patients with treatment failure.

      Pharmacological secondary endpoints:

        -  To determine minimum and maximum concentration in steady state of fosfomycin and
           cloxacillin.

        -  To evaluate pharmacokinetic variability of these concentration.

        -  To study the association between PK parameters and efficacy.

      Security secondary endpoints:

      To evaluate the security of cloxacillin and fosfomycin combination compared with cloxacillin
      monotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 21, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment success at day 7</measure>
    <time_frame>Day 7 after randomization. No microbiological failure after 12 weeks of randomization</time_frame>
    <description>Composite endpoint defined by all of the following criteria met after randomization: patient alive at day 7 AND stable or improved quick SOFA score (compared with baseline) at day 7 AND fever resolved at day 7 AND blood cultures negative for S. aureus starting at day 7 until Test of Cure visit (TOC, 12 weeks after randomization) and no isolation of S. aureus in another sterile site from day 8 until TOC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment success at TOC</measure>
    <time_frame>12 weeks after randomization</time_frame>
    <description>In case of achieving statistical differences in the primary endpoint, we will perform a hierarchical analysis of the treatment success at TOC, defined by presence of all of the following: patient alive AND no evidence of microbiological treatment failure defined as persistence of S. aureus bloodstream infection &gt; 7 days and no isolation of S. aureus from sterile site &gt; 14 days from randomization until TOC.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Methicillin Susceptible Staphylococcus Aureus Septicemia</condition>
  <arm_group>
    <arm_group_label>Combination therapy group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard therapy group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Combination therapy group</intervention_name>
    <description>Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.</description>
    <arm_group_label>Combination therapy group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard therapy group</intervention_name>
    <description>Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.</description>
    <arm_group_label>Standard therapy group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects, aged ≥ 18 years;

          -  MSSA bacteraemia: ≥ 1 positive blood culture(s) for MSSA in the first 72 h up to
             randomisation in patients with clinical suspicion of infection;

          -  Written informed consent of the participant or the legal representative.

        Exclusion Criteria:

          -  Severe clinical status with expected death &lt;48h.

          -  Severe hepatic cirrhosis (Child-Pugh C).

          -  Moderate-severe cardiac chronic failure (NYHA III-IV).

          -  Prosthetic endocarditis (need for concomitant antibiotic therapy active against S.
             aureus together with the study antibiotics for the first 7 days of the study).

          -  No pre-existing evidence of S. aureus fosfomycin non-susceptibility.

          -  Known hypersensitivity to cloxacillin or fosfomycin.

          -  Polymicrobial bacteraemia with more than one microorganism in blood cultures.

          -  A positive pregnancy test or pregnancy or lactation at the time of inclusion.

          -  Miastenia gravis.

          -  Participation in another clinical trial.

          -  Previous participation in the present clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sara Grillo, MD</last_name>
    <phone>0034 932 60 75 00</phone>
    <email>sarris.grillo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miquel Pujol Rojo, Md, PhD</last_name>
    <email>mpujol@bellvitgehospital.cat</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Cruces</name>
      <address>
        <city>Baracaldo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Silvia Gomez-Zorrilla</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Clínic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Laura Morata</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Joaquín Lopez Contreras</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Josep Trueta</name>
      <address>
        <city>Girona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Xavier Salgado</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Arnau de Vilanova</name>
      <address>
        <city>Lleida</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Alfredo Jover</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Lucus Agustí</name>
      <address>
        <city>Lugo</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Maria José García País</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Rafael Sanjuan</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Sant Joan</name>
      <address>
        <city>Reus</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Simona Iftimie</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Taulí</name>
      <address>
        <city>Sabadell</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Oriol Gasch</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Virgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Luis Eduardo López-Cortés</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Joan XXIII</name>
      <address>
        <city>Tarragona</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Graciano García Pardo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Mùtua de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <country>Spain</country>
      </address>
    </facility>
    <contact>
      <last_name>Lucia Boix</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bergin SP, Holland TL, Fowler VG Jr, Tong SYC. Bacteremia, Sepsis, and Infective Endocarditis Associated with Staphylococcus aureus. Curr Top Microbiol Immunol. 2017;409:263-296. doi: 10.1007/82_2015_5001.</citation>
    <PMID>26659121</PMID>
  </reference>
  <reference>
    <citation>van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. 2012 Apr;25(2):362-86. doi: 10.1128/CMR.05022-11. Review.</citation>
    <PMID>22491776</PMID>
  </reference>
  <reference>
    <citation>Gasch O, Camoez M, Dominguez MA, Padilla B, Pintado V, Almirante B, Molina J, Lopez-Medrano F, Ruiz E, Martinez JA, Bereciartua E, Rodriguez-Lopez F, Fernandez-Mazarrasa C, Goenaga MA, Benito N, Rodriguez-Baño J, Espejo E, Pujol M; REIPI/GEIH Study Groups. Predictive factors for mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infection: impact on outcome of host, microorganism and therapy. Clin Microbiol Infect. 2013 Nov;19(11):1049-57. doi: 10.1111/1469-0691.12108. Epub 2013 Jan 17.</citation>
    <PMID>23331461</PMID>
  </reference>
  <reference>
    <citation>Minejima E, Mai N, Bui N, Mert M, Mack WJ, She RC, Nieberg P, Spellberg B, Wong-Beringer A. Defining the Breakpoint Duration of Staphylococcus aureus Bacteremia Predictive of Poor Outcomes. Clin Infect Dis. 2020 Feb 3;70(4):566-573. doi: 10.1093/cid/ciz257.</citation>
    <PMID>30949675</PMID>
  </reference>
  <reference>
    <citation>Gudiol F, Aguado JM, Almirante B, Bouza E, Cercenado E, Domínguez MÁ, Gasch O, Lora-Tamayo J, Miró JM, Palomar M, Pascual A, Pericas JM, Pujol M, Rodríguez-Baño J, Shaw E, Soriano A, Vallés J. Diagnosis and treatment of bacteremia and endocarditis due to Staphylococcus aureus. A clinical guideline from the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC). Enferm Infecc Microbiol Clin. 2015 Nov;33(9):625.e1-625.e23. doi: 10.1016/j.eimc.2015.03.015. Epub 2015 May 1.</citation>
    <PMID>25937457</PMID>
  </reference>
  <reference>
    <citation>Thwaites GE, Scarborough M, Szubert A, Nsutebu E, Tilley R, Greig J, Wyllie SA, Wilson P, Auckland C, Cairns J, Ward D, Lal P, Guleri A, Jenkins N, Sutton J, Wiselka M, Armando GR, Graham C, Chadwick PR, Barlow G, Gordon NC, Young B, Meisner S, McWhinney P, Price DA, Harvey D, Nayar D, Jeyaratnam D, Planche T, Minton J, Hudson F, Hopkins S, Williams J, Török ME, Llewelyn MJ, Edgeworth JD, Walker AS; United Kingdom Clinical Infection Research Group (UKCIRG). Adjunctive rifampicin for Staphylococcus aureus bacteraemia (ARREST): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2018 Feb 17;391(10121):668-678. doi: 10.1016/S0140-6736(17)32456-X. Epub 2017 Dec 14.</citation>
    <PMID>29249276</PMID>
  </reference>
  <reference>
    <citation>Grillo S, Cuervo G, Carratalà J, Grau I, Pallarès N, Tebé C, Guillem Tió L, Murillo O, Ardanuy C, Domínguez MA, Shaw E, Gudiol C, Pujol M. Impact of β-Lactam and Daptomycin Combination Therapy on Clinical Outcomes in Methicillin-susceptible Staphylococcus aureus Bacteremia: A Propensity Score-matched Analysis. Clin Infect Dis. 2019 Oct 15;69(9):1480-1488. doi: 10.1093/cid/ciz018.</citation>
    <PMID>30615122</PMID>
  </reference>
  <reference>
    <citation>Grabein B, Graninger W, Rodríguez Baño J, Dinh A, Liesenfeld DB. Intravenous fosfomycin-back to the future. Systematic review and meta-analysis of the clinical literature. Clin Microbiol Infect. 2017 Jun;23(6):363-372. doi: 10.1016/j.cmi.2016.12.005. Epub 2016 Dec 9. Review.</citation>
    <PMID>27956267</PMID>
  </reference>
  <reference>
    <citation>Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K, Hróbjartsson A, Mann H, Dickersin K, Berlin JA, Doré CJ, Parulekar WR, Summerskill WS, Groves T, Schulz KF, Sox HC, Rockhold FW, Rennie D, Moher D. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013 Feb 5;158(3):200-7. doi: 10.7326/0003-4819-158-3-201302050-00583.</citation>
    <PMID>23295957</PMID>
  </reference>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 20, 2019</study_first_submitted>
  <study_first_submitted_qc>May 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2019</study_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Institut d'Investigació Biomèdica de Bellvitge</investigator_affiliation>
    <investigator_full_name>Miquel Pujol</investigator_full_name>
    <investigator_title>Principal Investigator, Medical Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bacteremia</mesh_term>
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

